Recent advances in acute promyelocytic leukaemia [version 1; referees: 3 approved]

Abstract

Acute promyelocytic leukaemia (APML) is a subtype of leukaemia arising from a distinct reciprocal translocation involving chromosomes 15 and 17, which results in the PML-RARA fusion gene. Over the past three decades, APML has been transformed from a highly fatal disease to a highly curable one. This drastic improvement is because of the introduction of a new treatment strategy with all-trans retinoic acid and, more recently, arsenic trioxide. The revolutionary treatment of APML has also paved the way for a new cancer treatment, which is genetically targeted therapy. In this review, we look into this amazing journey of transformation and provide recent advances in the management of APML.

Keywords

• Cancer Therapeutics
• Genetics of the Immune System
• Leukemia & Proliferative Disorders of Hematic Cells
• Pharmacogenomics
• Toxicology